Company intelligence / Profile preview

Biomay AG

Vienna, Vienna, Austriabiomay.com ↗

Ownership: Private
Employees: ~68
Development stage: Commercial

Overview

Biomay is a commercial-stage CDMO that recently obtained FDA approval for manufacturing Cas9 nuclease (April 28, 2025) and now offers lipid-nanoparticle formulation services for RNA pharmaceuticals (March 2025). They also distribute lentivirus starting plasmids off-the-shelf[2].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Plasmid DNA (pDNA)messenger RNA (mRNA)recombinant proteinsCas9 nuclease
Industry: Contract Manufacturing Organization

Partnerships

Vertex Pharmaceuticals (manufacturing Cas9 for CASGEVY®)Biontech/Pfizer (producing starting material for COVID-19 mRNA vaccine)[5]

Beyond the preview

Go deeper on Biomay AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomay AG.

Explore the full profile